MedTrace Logo

Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial

NCT00420134 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-09-17

No results posted yet for this study

Summary

The methods for separation of mesenchymal stem cell were established in 2001. These cells can differentiate to osteocytes, hepatocytes, chondrocytes, myocytes and etc,. In this study the investigators try to separate mesenchymal stem cell from end stage liver disease, then these cells will be differentiated to progenitor of hepatocytes, finally , the investigators injected these cells into portal vein under ultrasound guide. The investigators determine the effects of injected cells in reestablishment of liver function.

Conditions

  • Liver Failure
  • Cirrhosis

Interventions

PROCEDURE

injection of progenitor of hepatocyte drived from Mesenchymal stem cell

Sponsors & Collaborators

  • Tarbiat Modarres University

    collaborator OTHER

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Mohammad Reza Zali, MD · Research center of Gastroenterology and Liver Disease

  • Pedram Kharaziha, MD · Research Center for Gastroenterology and Liver Diseases

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2009-05-31
Completion
2009-06-30

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00420134 on ClinicalTrials.gov